Intec Pharma (NTEC) Prices 5.03M Ordinary Share IPO at $6/Share

Intec Pharma Ltd. (the "Company") (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced the pricing of its initial public offering in the United States of 5,025,000 of its ordinary shares at a price to the public of $6.00 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 753,750 ordinary shares at the public offering price. The Company anticipates that the total gross proceeds from the offering will be approximately $30.15 million before deducting underwriting discounts and commissions and other offering expenses. The Company plans to use the net proceeds from the offering to fund its Phase III clinical trial for its leading product candidate, Accordion Pill Carbidopa/Levodopa, and its continued development, and for working capital, capital expenditures and other general corporate purposes, including a Phase I clinical trial that the Company expects to initiate in the second half of 2015 for one of its early stage pipeline products.

The Company's ordinary shares are scheduled to begin trading on The NASDAQ Capital Market on August 4, 2015 under the symbol "NTEC". The offering is expected to close on August 7, 2015, subject to customary closing conditions.

Maxim Group LLC and Roth Capital Partners are acting as joint book-running managers for the offering.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• After-Hours Stock Movers: FDX, CBRS, NKE
• UK’s EG Group reportedly files for US IPO worth about $1 billion